CA2609268A1 — Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents
Assigned to University of Utah Research Foundation Inc · Expires 2006-11-30 · 19y expired
What this patent protects
Described are methods and compositions for treating tumors, such as drug-sensitive tumors, inoperable tumors, poorly vascularized tumors, and multidrug resistant tumors, by intravenous or direct intratumoral injection of compositions comprising microemulsions and polymeric micell…
USPTO Abstract
Described are methods and compositions for treating tumors, such as drug-sensitive tumors, inoperable tumors, poorly vascularized tumors, and multidrug resistant tumors, by intravenous or direct intratumoral injection of compositions comprising microemulsions and polymeric micelle-encapsulated biologically active agents. The methods and compositions also include microemulsions converting into microbubbles in situ upon injection. The methods disclosed optionally including applying a micelle disruption method such as ultrasound. Also disclosed are methodologies of imaging administration of agents in tissues using streams of microemulsions which create microbubbles in situ upon injection. The methods and compositions also include enhancement of tumor treatment through use of microemulsions which create microbubbles in situ, upon injection, as cavitation nuclei. The methods and compositions are also useful in enhancing intracellular drug delivery.
Drugs covered by this patent
- Risperdal (risperidone) · Johnson & Johnson (Janssen)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.